Immatics N.V. (IMTX) is a Biotechnology company in the Healthcare sector, currently trading at $10.95. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 2 out of 7 criteria passed.
Analyst consensus target is IMTX = $21 (+91.8% upside).
Valuation: IMTX trades at a trailing Price-to-Earnings (P/E) of -6.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 8.04.
Financials: revenue is $48M, +16.9%/yr average growth. Net income is $189M (loss), growing at -527.6%/yr. Net profit margin is -390.9% (negative). Gross margin is 100% (+61.8 pp trend).
Balance sheet: total debt is $16M against $484M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 11.72 (strong liquidity). Debt-to-assets is 2.8%. Total assets: $562M.
Analyst outlook: 8 / 8 analysts rate IMTX as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 61/100 (Pass), Growth 48/100 (Partial), Past 50/100 (Partial), Health 67/100 (Partial), Moat 62/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
